

Publikationsverzeichnis

Prof. Dr. med. Thomas Vogt

Stand 12/16

Publikationen gesamt	290
Originalarbeiten	220
Kumulativer IF	809,9
Durchschnittlicher IF	3,7
Arbeiten mit IF > 10	7
Arbeiten mit IF > 5	17
h-Index	31

Die Auflistung ist gegliedert wie folgt:

A Laborwissenschaftliche Originalarbeiten - Senior-/Erstautorenschaften	44
B Laborwissenschaftliche Originalarbeiten - Koautorenschaften	59
C Klinisch-wissenschaftliche Originalarbeiten	117
D <u>Übersichten</u>/<u>Buchbeiträge</u>	70

A Laborwissenschaftliche Arbeiten - Senior-/Erstautorenschaften - chronologisch (44)

1. Müller CS, Pföhler C, Schiekofer C, Körner R, **Vogt T**. Primary cutaneous carcinosarcomas: A morphological histogenetic concept revisited. **Am J Dermatopathol** 2014 36:328-39 **IF 1,3**
2. Maurer A, Roesch A, Hafner C, Stempf T, Wild P, Meyer S, Landthaler M, **Vogt T**. Identification of new genes associated with melanoma. **Exp Dermatol** 20:502-7, 2011 **IF 4,2**
3. Coras B, Landthaler M, Stolz W, **Vogt T**. Dysplastic Melanocytic Nevi of the Lower Leg: Sex- and Site-Specific Histopathology. **Am J Dermatopathol** 32:599-602, 2010 **IF 1,3**
4. Hafner C, Landthaler M, Mentzel T, **Vogt T**. FGFR3 and PIK3CA mutations in stucco keratosis and dermatosis papulosa nigra. **Br J Dermatol** 162:508-12, 2010 **IF 4,4**
5. Hafner C, di Martino E, Pitt E, Stempf T, Tomlinson D, Hartmann A, Landthaler M, Knowles M, **Vogt T**. FGFR3 mutation affects cell growth, apoptosis and attachment in keratinocytes. **Exp Cell Res** 316:2008-16, 2010 **IF 3,6**
6. Hafner C, Landthaler M, **Vogt T**. Activation of the PI3K/AKT signaling pathway in nonmelanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations. **Exp Dermatol** 19:222-227, 2010 **IF 4,2**
7. Babilas P, Fiebig BS, Aslanidis C, Hansen J, Röcken C, Schroeder J, Schmitz G, Weber BH, Landthaler M, **Vogt T**. Identification of an oncostatin M receptor mutation associated with familial primary cutaneous amyloidosis. **Br J Dermatol** 161:944-7, 2009 **IF 4,3**
8. Meyer S, **Vogt T (equally contr.)**, Landthaler M, Berand A, Reichle A, Bataille F, Marx A, Menz A, Hartmann A, Kunz-Schughart L, Wild PJ. Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) are stage-dependent prognostic markers of malignant melanoma. **PPAR Res** ID 848645, 11 pages, 2009 **IF -**
9. Hafner C, Stoehr R, van Oers JMM, Zwarthoff EC, Hofstääedter F, Klein C, Landthaler M, Hartmann A, **Vogt T**. Absence of BRAF, FGFR3 and PIK3CA mutations discriminates lentigo simplex from melanocytic nevus. **J Invest Dermatol** 129:2730-5, 2009 **IF 5,5**
10. Hafner C, Klein A, Landthaler M, **Vogt T**. Clonality of basal cell carcinoma arising in an epidermal nevus - new insights provided by molecular analysis. **Dermatology**, 218:278-81, 2008 **IF 1,8**
11. Hafner C, Stoehr R, van Oers J, Zwarthoff E, Hofstädter F, Landthaler M, Hartmann A, **Vogt T**. FGFR3 and PIK3CA mutations are involved in the molecular pathogenesis of solar lentigo. **Br J Dermatol**, 160(3):546-51, 2008 **IF 3,5**
12. Roesch A, Mueller AM, Stempf T, Moehle C, Landthaler M, **Vogt T**. RBP2-H1/JARID1B is a transcriptional regulator with a tumor suppressive potential in melanoma cells. **Int J Cancer** 122: 1047–1057, 2008 **IF 4,4**
13. Hafner C, Landthaler M, Happle R, **Vogt T**. Nevus Marginatus: A distinct Type of Epidermal nevus or merely a variant of nevus sebaceus ? **Dermatology** 216:236–238, 2008 **IF 1,8**

14. Hafner C, Stempf T, Bäumler W, Hohenleutner U, Landthaler M, **Vogt T** . Gene expression profiling of melanocytes following Q-switched Ruby laser irradiation. **Dermatology** 216:6-13, 2008 **IF 1,8**
15. Bundscherer A, Hafner C, Maisch T, Becker B, Landthaler M, **Vogt T** . Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines. **Oncol Rep** 19:547-553, 2008. **IF 1,3**
16. Roesch A, Becker B, Bentink S, Spang R, Vogl A, Hagen I, Landthaler M, Vogt T. Ataxia Telangiectasia-Mutated Gene Is a Possible Biomarker for Discrimination of Infiltrative Deep Penetrating Nevi and Metastatic Vertical Growth Phase Melanoma. **Cancer Epidemiol Biomarkers Prev** 16:2486-2490, 2007. **IF 4,7**
17. Hafner C, Hartmann A, van Oers J, Stoehr R, Zwarthoff EC, Hofstaedter F, Landthaler M, **Vogt T** . *FGFR3* mutations in seborrheic keratoses are already present in flat lesions and associated with age and localization. **Mod Pathol** 20:895-903, 2007 **IF 3,7**
18. Hafner C, Schiemann V, Rütten A, Coras B, Landthaler M, Reifenberger J, **Vogt T** . PTCH mutations are not mainly involved in the pathogenesis of sporadic trichoblastomas. **Human Pathol** 38:1496-500, 2007 **IF 2,8**
19. Meyer S, Orso E, Schmitz G, Landthaler M, **Vogt T** . Lubrol-RAFTs in melanoma cells: A molecular platform for tumor promoting ephrin-B2-integrin- β 1-interaction. **J Invest Dermatol** 127:1615-21, 2007 **IF 4,2**
20. Hafner C, van Oers JM, Hartmann A, Landthaler M, Stoehr R, Blaszyk H, Hofstaedter F, Zwarthoff EC, Vogt T. Spectrum of *FGFR3* mutations in multiple intraindividual seborrheic keratoses. **J Invest Dermatol** 127: 1883-1885, 2007 **IF 4,2**
21. Roesch A, Becker B, Schneider-Brachert W, Landthaler M, **Vogt T** . Re-expression of the retinoblastoma-binding protein 2-homolog 1 reveals tumor suppressive functions in highly metastatic melanoma cells. **J Invest Dermatol** 126:1850-9, 2006 **IF 4,2**
22. Hafner C, van Oers JM, Hartmann A, Landthaler M, Stoehr R, Blaszyk H, Hofstaedter F, Zwarthoff EC, Vogt T. High frequency of *FGFR3* mutations in adenoid seborrheic keratoses. **J Invest Dermatol**, 126: 2404-2407, 2006 **IF 4,2**
23. Hafner C, Landthaler M, **Vogt T** . Expression profile of Eph receptors and ephrin ligands in human skin and downregulation of EphA1 in nonmelanoma skin cancer. **Mod Pathol** 19:1369-77, 2006 **IF 3,3**
24. Rösch A, Witschier S, Landthaler M, **Vogt T** . Loss of dipeptidyl peptidase IV discriminates malignant melanoma from deep penetrating nevi. **Mod Pathol**, 19:1378-85, 2006 **IF 3,3**
25. Meyer S, Hafner C, Guba M, Flegel S, Geissler EK, Becker B, Koehl G, Orsó E, Landthaler M, **Vogt T** . ephrin-B2 overexpression enhances integrin-mediated ECM-attachment and migration of B16 melanoma cells. **Int J Oncol** 27:1197-206, 2005 **IF 3,1**
26. Roesch A, Becker B, Schneider-Brachert W, Meyer S, Wild P, Hafner C, Landthaler M, **Vogt T** . Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding protein downregulated in malignant melanomas. **Mod Pathol**, 18:1249-57, 2005 **IF 3,3**
27. Hafner C, Meyer S, Hagen I, Becker B, Rösch A, Landthaler M, **Vogt T** . Ephrin-B reverse signaling induces expression of wound healing associated genes in IEC6 intestinal epithelial cells. **W J Gastroenterol** 11:4511-8, 2005 **IF (2003) 3,3**

28. Hafner C, Meyer M, Langmann T, Schmitz G, Bataille F, Becker B, Hagen I, Rogler G, Schölmerich J, Landthaler M, **Vogt T**. EphB/ephrin-B signaling enhances wound healing of intestinal epithelium. **W J Gastroenterol** 11:4024-31, 2005 **IF 3,3**
29. Roesch A, Becker B, Meyer S, Hafner C, Wild J, Landthaler M, **Vogt T**. Overexpression and hyperphosphorylation of pRb in the progression of malignant melanoma. **Mod Pathol** 18:565-72, 2005 **IF 3,3**
30. Becker B, Stolz W, Landthaler M, **Vogt T**. LPC-microdissection combined with microarray analysis identifies genes discriminating melanocytic nevi and malignant melanomas. **J Invest Dermatol**, 122:361-368, 2004 **IF 4,2**
31. Hafner C, Schmitz G, Meyer S, Bataille F, Langmann T, Dietmaier W, Landthaler M, **Vogt T**. Differential gene expression of Eph receptors and ephrins in various human normal tissues and cancers. **Clin Chem**, 50:490-499, 2004 **IF 6,5**
32. Becker B, Multhoff G, Farkas B, Wild PJ, Landthaler M, Stolz W, **Vogt T**. HSP90 is up-regulated in melanoma progression: Possible implications for vaccine therapy. **Exp Dermatol** 13: 27–32, 2004 **IF 2,0**
33. Hafner C, Bataille F, Meyer S, Becker B, Roesch A, Landthaler M, **Vogt T**. Loss of EphB6 expression in metastatic melanoma. **Int J Oncol** 23:1553-9, 2003 **IF 3,1**
34. Hafner C, Hartmann A, Knuechel R, Dietmaier W, Landthaler M, **Vogt T**. Molecular genetic analysis excludes implantation metastasis of basal cell carcinomas. **Arch Pathol Lab Med** 127:1221-4, 2003 **IF 1,3**
35. Rumpler G, Becker B, Hafner C, McClelland M, Stolz W, Landthaler M, Schmitt R, Bosserhoff AK, **Vogt T**. Identification of differentially expressed genes in models of melanoma progression by cDNA array analysis: SPARC, MIF and a novel cathepsin protease characterize aggressive phenotypes. **Exp Derm**, 12: 761-771, 2003 **IF 2,0**
36. **Vogt T**, McClelland M, Jung B, Popova S, Bogenrieder T, Becker B, Rumpler G, Landthaler L, Stolz W. Progression and NSAID-induced Apoptosis in Malignant Melanomas are independent of Cyclooxygenase II. **Melanoma Res**, 11:587-599, 2001 **IF 2,2**
37. **Vogt T**, Kroiss M, McClelland M, Gruss C, Bosserhoff AK, Becker B, Rumpler G, Bogenrieder T, Landthaler L, Stolz W. Deficiency of a novel retinoblastoma binding protein 2 homolog is a consistent feature of malignant melanomas. **Lab Invest** 79:1615-27, 1999 **IF 4,4**
38. **Vogt T**, Stolz W, Welsh J, Jung B, Kerbel RS, Kobayashi H, Landthaler M, McClelland M: Overexpression of LERK-5/EPLG5 mRNA: A novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas. **Clin Cancer Res** 4: 791-797, 1998 **IF 6,5**
39. **Vogt T**, Welsh J, Stolz W, Mathieu-Daude F, Kullmann F, Jung B, Landthaler M, McClelland M: RNA fingerprinting displays UV B specific disruption of transcriptional control in human melanocytes. **Cancer Res** 57: 3554-3561, 1997 **IF 8,6**
40. **Vogt T**, Zipperer KH, Vogt A, Hölzel D, Landthaler M, Stolz W: p53-protein and ki67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin. **Histopathology** 30: 57-63, 1997 **IF 3,0**

41. **Vogt T**, Stolz W, Landthaler M, Rüschoff J, Schlegel J: Non-radioactive arbitrarily primed PCR: A novel technique for detection of genetic defects in skin tumors. **J Invest Dermatol** 106:194-197, 1996 **IF 4,2**
42. **Vogt T**, Stolz W, Gläßl A, Abmayr W, Hohenleutner U, Schmöckel Ch, Schiffner R, Landthaler M. Multivariate DNA-cytometry discriminates between Spitz nevi and malignant melanomas because large polymorphic nuclei in Spitz nevi are not aneuploid. **Am J Dermatopathol** 18: 142-150, 1996 **IF 1,1**
43. **Vogt T**, Stolz W, Hohenleutner U, Schiffner R, Landthaler M: Prognostic significance of DNA cytometry in comparison with histologic measurements in malignant melanomas. **Rec Results Cancer Res** 139:195-204, 1994 **IF --**
44. **Vogt T**, Stolz W, Braun-Falco O, Kaudewitz P, Eckert F, Abmayr W, Dummer R, Burg G: Prognostic significance of DNA cytometry in cutaneous malignant lymphomas by computerized DNA-image cytometry. **Cancer** 68: 1095-1100, 1991 **IF 4,0**

B Laborwissenschaftliche Arbeiten - Koautorenschaften - chronologisch (59)

1. Weinhold A, Obeid R, **Vogt T**, Reichrath J. Prospective Investigation of 25(OH)D3 Serum Concentration Following UVB Narrow Band Phototherapy in Patients with Psoriasis and Atopic Dermatitis. **Anticancer Res** 36:1439-44, 2016 **IF 1,83**
2. Rossberg W, Saternus R, Wagenpfeil S, Kleber M, März W, Reichrath S, **Vogt T**, Reichrath J. Human Pigmentation, Cutaneous Vitamin D Synthesis and Evolution: Variants of Genes (SNPs) Involved in Skin Pigmentation Are Associated with 25(OH)D Serum Concentration. **Anticancer Res** 36:1429-37, 2016 **IF 1,83**
3. Saul S, Gibhardt CS, Schmidt B, Lis A, Pasiëka B, Conrad D, Jung P, Gaupp R, Wönnenberg B, Diler E, Stanisz H, **Vogt T**, Schwarz EC, Bischoff M, Herrmann M, Tschernig T, Kappl R, Rieger H, Niemyer BA, Bogeski I. A calcium-redox feedback loop controls human monocyte immune responses: The role of ORAI Ca²⁺ channels. **Science Signaling** 8;9(418), 2016 **IF 6,28**
4. Glatthaar H, Katto J, **Vogt T**, Mahlkecht U. Estrogen Receptor Alpha (ESR1) Single-Nucleotide Polymorphisms (SNPs) Affect Malignant Melanoma Susceptibility and Disease Course. **Genet Epigenet** 24;8:1-6, 2016 **IF -**
5. Mathes C, Melero A, Conrad P, **Vogt T**, Rigo L, Selzer D, Prado WA, De Rossi C, Garrigues TM, Hansen S, Guterres SS, Pohlmann AR, Beck RC, Lehr CM, Schaefer UF. Nanocarriers for optimizing the balance between interfollicular permeation and follicular uptake of topically applied clobetasol to minimize adverse effects. **J Control Release** 10;223:207-14, 2016 **IF 7,71**
6. Cierlitz M, Chauvistré H, Bogeski I, Zhang X, Hauschild A, Herlyn M, Schadendorf D, **Vogt T**, Roesch A. Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations. **Exp Dermatol** 24:155-7, 2015 **IF 3,76**

7. Schub D, Janssen E, Leyking S, Sester U, Assmann G, Hennes P, Smola S, **Vogt T**, Rohrer T, Sester M, Schmidt T. Altered Phenotype and Functionality of Varicella Zoster Virus-Specific Cellular Immunity in Individuals With Active Infection. **J Infect Dis** 15;211:600-12, 2015 **IF 5,99**
8. Raber AS, Mittal A, Schäfer J, Bakowsky U, Reichrath J, **Vogt T**, Schaefer UF, Hansen S, Lehr CM. Quantification of nanoparticle uptake into hair follicles in pig ear and human forearm. **J Control Release** 10;179:25-32, 2014 **IF 7,63**
9. Saternus R, Pilz S, Gräber S, Kleber M, März W, **Vogt T**, Reichrath J. A closer look at evolution: variants (SNPs) of genes involved in skin pigmentation, including EXOC2, TYR, TYRP1 and DCT, are associated with 25(OH)D serum concentration. **Endocrinology** 2015 156:39-47 **IF 4,50**
10. Bade B, Zdebik A, Wagenpfeil S, Gräber S, Geisel J, **Vogt T**, Reichrath J. Low serum 25-hydroxyvitamin d concentrations are associated with increased risk for melanoma and unfavourable prognosis. epub ahead 2014, **PLoS One** **IF 3,73**
11. Cierlitz M, Chauvistré H, Bogeski I, Zhang X, Hauschild A, Herlyn M, Schadendorf D, **Vogt T**, Roesch A. epub ahead 2014, **Exp Dermatol** **IF 4,2**
12. Stanisz H, Saul S, Müller CS, Kappl R, Niemeyer BA, **Vogt T**, Hoth M, Roesch A, Bogeski I. Inverse regulation of melanoma growth and migration by Orail1/STIM2-dependent calcium entry. **Pigment Cell & Melanoma Research** 27(3):442-53, 2014 **IF 5,84**
13. Schäfer A, Emmert S, Kruppa J, Schubert S, Tzetzkov M, Mössner R, Reich K, Berking C, Volkenandt M, Pföhler C, Schön MP, **Vogt T**, König IR, Reichrath J. No association of vitamin D metabolism related polymorphisms and melanoma risk as well as melanoma prognosis: a case control study. **Arch Dermatol Res** 304:353-61, 2012 **IF 2,71**
14. Meyer S, Fuchs TJ, Bosserhoff Ak, Hofstädter F, Pauer A, Roth V, Buhmann JM, Moll I, Anagnostou N, Brandner JM, Ickenberg K, Moch H, Landthaler M, **Vogt T**, Wild PJ. A seven-marker signature and clinical outcome in malignant melanoma: a large scale tissue microarray study with two independent patient cohorts. **PLoS One** e38222, 2012 **IF 3,73**
15. Marko L, Paragh G, Ugoscai P, Boettcher A, **Vogt T**, Schling P, Balogh A, Tarabin V, Orso E, Wikonkal N, Mandl J, Remenyk E, Schmitz G. Keratinocyte ATB binding cassette transporter expression is regulated by UV light. **J Photochem Photobiol B** 116:79-88, 2012 **IF 3,11**
16. Groesser L, **Vogt T**, Happle R, Herschberger E, Mickler M, Landthaler M, Hafner C. Naevus marginatus revisited: a combined organoid and nonorganoid epidermal nevus caused by HRAS mutation. **Br J Dermatol** 168: 892-4, 2013 **IF 3,76**
17. Körner R, Preuss KD, Fadle N, Madjidi D, Neumann F, Bergeler L, Gräber S, Müller CS, Grünhage F, Pfreundschuh M, Lammert F, **Vogt T**, Pföhler C. Serum antibodies against CD28 – a new potential marker of dismal prognosis in melanoma patients. **PLoS One** 8: e58087, 2013 **IF 3,73**
18. Schreml S, Weber BH, Schröder J, Siegmund H, Schaller J, **Vogt T**, Landthaler M, Schönbuchner I, Röcken C, Babilas P. Familial primary localized cutaneous amyloidosis with an oncostatin receptor β mutation Pro694Leu. **Clin Exp Dermatol** 38: 932-5, 2013 **IF 1,33**

19. Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann KM, Speicher D, Körbel C, Laschke MW, Gimotty PA, Philipp SE, Krause E, Pätzold S, Villanueva J, Krepler C, Fukunaga-Kalabis M, Hoth M, Bastian BC, **Vogt T**, Herlyn M. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow cycling JARID1B high cells. **Cancer Cell** 23:811-25, 2013 **IF 24,76**
20. Pföhler C, Knöpfen T, Körner R, Vogt T, Rösch A, Müller CS. Maspin expression in the invasive margin of primary melanomas may reflect an aggressive tumor phenotype. **JDDG** 2013 epub ahead of print **IF 1,4**
21. Wang T, Ge Y, Xiao M, Lopez-Coral A, Li L, Roesch A, Huang C, Alexander P, **Vogt T**, Xu X, Hwang WT, Lieu M, Belser E, Liu R, Somasundaram R, Herlyn M, Kaufmann RE. SECTM1 produced by tumor cells attracts human monocytes via CD7-mediated activation of the PI3K pathway. **J Invest Dermatol** 2013 epub ahead of print **IF 6,19**
22. Stanisiz H, Stark A, Kilch T, Schwarz EC, Müller, CSL, Peinelt C, Hoth M, Niemeyer BA, **Vogt T**, Bogeski I. ORA11 Ca²⁺ Channels Control Endothelin-1-Induced Mitogenesis and Melanogenesis in Primary Human Melanocytes. **J Invest Dermatol** 132:1443-51, 2012 **IF 6,3**
23. Essa S, Reichrath S, Mahlknecht U, Montenarh M, **Vogt T**, Reichrath J. Signature of VDR miRNAs and epigenetic modulation of vitamin D signaling in melanoma cell lines. **Anticancer Res** 32:383-9, 2012 **IF 1,7**
24. Köstner K, Denzer N, Koreng M, Reichrath S, Gräber S, Klein R, Tilgen W, **Vogt T**, Reichrath J. Association of genetic variants of the vitamin D receptor (VDR) with cutaneous squamous cell carcinomas (SCC) and basal cell carcinomas (BCC): a pilot study in a German population. **Anticancer Res** 32:327-33, 2012 **IF 1,7**
25. Amyere M, **Vogt T**, Hoo J, Brandrup F, Bygum A, Boon L, Vikkula M. KITLG Mutations Cause Familial Progressive Hyper- and Hypopigmentation. **J Invest Dermatol** 131(6):1234-9, 2011, **IF 6,3**
26. Oldak M, Tolzmann L, Wnorowski A, Podgórska MJ, Silling S, Lin R, Hiscott J, Müller CS, **Vogt T**, Smola H, Smola S. Differential regulation of human papillomavirus type 8 by interferon regulatory factor 3 and 7. **J Virol** 85:178-88, 2011 **IF 5,4**
27. Stanisiz H, Seifert M, Tilgen W, **Vogt T**, Rass K. Reciprocal responses of fibroblasts and melanocytes to α -MSH depending on MC1R polymorphisms. **Dermatoendocrinol** 4:259-65, 2011 **IF --**
28. Müller CS, Hiatt KM, **Vogt T**, Smoller B. Expression of CD163 in granulomatous dermatitis is not the tool that makes the difference. **JEADV** (epub ahead of print) 2011 **IF 3,3**
29. Meyer S, Wild PJ, **Vogt T**, Bataille F, Ehret C, Gantner S, Landthaler M, Klinkhammer-Schalke M, Hofstaedter F, Bosserhoff AK. Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma. **Exp Dermatol** 19: 251-7, 2010 **IF 4,2**
30. Bundscherer A, **Vogt T**, Köhl G, Landthaler M, Hafner C. Antiproliferative effects of rapamycin and celecoxib in angiosarcoma cell lines. **Anticancer Res** 30:4017-23, 2010 **IF 1,7**

31. Hafner C, Toll A, Fernández-Casad A, Earl J, Marqués M, Acquadro F, Méndez-Pertuz M, Urioste M, Malats N, Burns JE, Knowles MA, Cigudosa JC, Hartmann A, **Vogt T**, Landthaler M, Pujol RM, Real FX. Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors. **Proc Natl Acad Sci U S A** 107:20780-5, 2010 **IF: 9,8**
32. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Gimotty P, **Vogt T**, Herlyn M. The dynamic expression of JARID1B in a subpopulation of melanoma is required for continuous tumor growth. **Cell** 141:583–594, 2010 **IF 31,3**
33. Reichrath S, Müller CS, Gleissner B, Pfreundschuh M, Vogt T, Reichrath J. Notch- and vitamin D signaling in 1,25(OH)(2)D(3)-resistant glioblastoma multiforme (GBM) cell lines. **J Steroid Biochem Mol Biol** 121:420-4, 2010 **IF 2,9**
34. Trémezaygues L, Seifert M, **Vogt T**, Tilgen W, Reichrath J. 1,25-Dihydroxyvitamin D(3) modulates effects of ionizing radiation (IR) on human keratinocytes: in vitro analysis of cell viability/proliferation, DNA-damage and-repair. **J Steroid Biochem Mol Biol** 121:324-7, 2010 **IF 2,9**
35. Paragh G, Ugocsai P, **Vogt T**, Schling P, Kel AE, Tarabin V, Liebisch G, Orsó E, Markó L, Balogh A, Köbling T, Remenyik E, Wikonkál NM, Mandl J, Farwick M, Schmitz G. Whole genome transcriptional profiling identifies novel differentiation regulated genes in keratinocytes. **Exp Dermatol** 19:297-301, 2010 **IF 4,2**
36. Hafner C., T. **Vogt T**, Landthaler M, Müsebeck J. Somatic FGFR3 and PIK3CA mutations are present in familial seborrheic keratoses. **Br J Dermatol** 159:214-7, 2008 **IF: 2,7**
37. Hafner C, Lopez-Knowles E, Luis NM, Toll A, Baselga E, Fernandez-Casado A, Hernandez S, Ribe A, Mentzel T, Stoehr R, Hofstaedter F, Landthaler M, **Vogt T**, Pujol RM, Hartmann A, Real FX. Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. **PNAS** 104:13450–13454, 2007 **IF 9,6**
38. Hafner C, van Oers J, **Vogt T**, Landthaler M, Stoehr R, Blaszyk H, Hofstädter F, Zwarthoff E, Hartmann A. Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. **J Clin Invest** 116:2201-2207, 2006 **IF 14,2**
39. Wild PJ, Meyer S, Bataille F, Woenckhaus M, Ameres M, **Vogt T**, Landthaler M, Pauer A, Klinkhammer-Schalke M, Hofstaedter F, Bosserhoff A. High-throughput tissue microarray analysis of MTAP expression in melanocytic skin tumors. **Arch Dermatol** 142:471-6, 2006 **IF 3,5**
40. Chikaev N, Bykova E, Najakshin A, Mechetina L, Volkova O, Peklo M, Shevelev A, Vlasik T, Roesch A, **Vogt T**, A. Taranin. Cloning and characterization of human FCRL2. **Genomics**, 85:264-72, 2005 **IF 3,5**
41. Vogl A, Sartorius U, **Vogt T**, Roesch A, Landthaler M, Stolz W, Becker B. Gene expression profile changes between melanoma metastases and their daughter cell lines: implication for vaccination protocols. **J Invest Dermatol**, 124:401-4, 2005 **IF 4,2**
42. Roesch A, **Vogt T**, Stolz W, Dugas M, Landthaler M, Becker B. Discrimination between gene expression patterns in the invasive margin and the tumour core of malignant melanomas. **Melanoma Res** 13:503-9, 2003 **IF 2,2**

43. Becker B, **Vogt T**, Knüchel R, Stolz W. Transcriptome profiling of melanocytic cells from human malignant melanomas. **Meth Enzymol** 356:80-99, 2002 **IF 1,6**
44. Guba M, Steinbauer M, Ruhland V, Schutz A, Geissler EK, Anthuber M, **Vogt T**, Bosserhoff A, Jauch KW. Elevated MIA serum levels are predictors of poor prognosis after surgical resection of metastatic malignant melanoma. **Oncol Rep** 9:981-4, 2002 **IF 1,3**
45. Kroiss M, **Vogt T**, Schlegel J, Rüschoff J, Landthaler M, Stolz W. Microsatellite instability is restricted to the malignant melanomas with increased frequency in advanced stages. **Acta Dermato Venereol**, 81:242-5, 2001 **IF 1,6**
46. Becker B, **Vogt T**, Landthaler M, Stolz W. Detection of differentially regulated genes in keratinocytes by cDNA array hybridisation: Hsp27 and novel UV responsive genes. **J Invest Dermatol**, 116:983-988, 2001 **IF 4,2**
47. Schiffner R, Schiffner-Rohe J, **Vogt T**, Landthaler M, Wlotzke U, Cagnetta AB, Stolz W. Improvement of early recognition of lentigo maligna using dermatoscopy. **J Am Acad Dermatol** 42:25-32, 2000 **IF 3,0**
48. Mathieu-Daude F, Trenkle T, Welsh J, Jung B, **Vogt T**, McClelland M. Identification of differentially expressed genes using RNA fingerprinting by arbitrarily primed polymerase chain reaction. **Methods Enzymol** 303: 309-24, 1999 **IF 1,6**
49. Kroiss M, Bosserhoff A, **Vogt T**, Buettner R, Bogenrieder T, Landthaler M, Stolz W. Loss of expression or mutations in the p73 tumour suppressor gene are not involved in the pathogenesis of malignant melanomas. **Melanoma Res** 8: 504-9, 1998 **IF 2,2**
50. Jung B, **Vogt T**, Mathieu-Daude F, Welsh J, McClelland M, Trenkle T, Weitzel C, Kullmann F. Estrogen-responsive RING finger mRNA induction in gastrointestinal carcinoma cells following bile acid treatment. **Carcinogenesis** 19:1901-6, 1998 **IF 4,7**
51. McClelland M, Honeycutt R, Mathieu-Daude F, **Vogt T**, Welsh J. RNA arbitrarily primed PCR. **Methods Mol Biol** 85:13-24, 1997 **IF --**
52. Mathieu-Daude F, Welsh J, **Vogt T**, McClelland M. DNA rehybridisation during PCR: The „C_t effect“ and its consequences. **Nucleic Acids Res** 24:2080-2086, 1996 **IF 6,6**
53. Schlegel J, **Vogt T**, Münkkel K, Rüschoff J. DNA fingerprinting of mammalian cell lines using non-radioactive arbitrarily primed PCR (AP-PCR). **Biotechniques** 20:178-180, 1996 **IF 2,4**
54. Stolz W, Schiffner R, Pillet L, **Vogt T**, Harms H, Schindewolf T, Landthaler M, Abmayr W: Improvement of monitoring of melanocytic skin lesions with the use of a computerized acquisition and surveillance unit with a skin surface microscopic television camera. **J Am Acad Dermatol** 35: 202-207, 1996 **IF 3,0**
55. Stolz W, **Vogt T**, Landthaler M, Hempfer S, Bingler P, Abmayr W: Differentiation between malignant melanoma and benign melanocytic nevi by computerized DNA cytometry of imprint specimens. **J Cutan Pathol** 21:7-15, 1994 **IF 1,6**
56. Nachbar F, Stolz W, Merkle T, Cagnetta A, **Vogt T**, Landthaler M, Plewig G: The ABCD rule of dermatoscopy: high prospective value in the diagnosis of doubtful melanocytic skin lesions. **J Am Acad Dermatol** 30:551-559, 1994 **IF 3,0**

57. Smolle J, Stolz W, Bahmer FA, el-Gammal S, Heinisch G, Mattfeld T, Nilles M, Otto F, Peter RU, Soyer HP, Sepp N, **Vogt T**: Analytical morphology in dermatology - Technical aspects and practical applications. **J Am Acad Dermatol** 29:86-97, 1993 **IF 3,0**
58. Dummer R, Nestle F, Wiede J, Schäfer E, Röger J, Becker JC, **Vogt T**, Burg G: Coincidence of increased interleukin 2 receptors, diminished natural killer cell activity and progressive disease in cutaneous T cell lymphomas. **Eu J Dermatol** 1:1375-1384, 1991 **IF 1,0**
59. Stolz W, **Vogt T**, Braun-Falco O, Abmayr W, Eckert F, Kaudewitz P, Vieluf D, Bieber K, Burg G: Differentiation between lymphomas and pseudolymphomas of the skin by computerized DNA-image cytometry. **J Invest Dermatol** 94: 254-260, 1990 **IF 4,2**

C Klinisch-wissenschaftliche Arbeiten – chronologisch (117)

1. Müller C, Zdebik A, Pföhler C, **Vogt T**. Ichthyosiformer Morphen-wandel einer erythrodermen Mycosis fungoides unter extrakorporaler Photopherese Therapie **Akt Dermatol** 42: 424-427, 2016
2. Pföhler C, Klotz M, Wehler T, **Vogt T**, Müller C. A slowly growing orange patch on the cheek: Diagnosis of lupus vulgaris 20 years after onset of first skin changes. **Dermatol Ther** 2016 – epub ahead. **IF 1,29**
3. Müller CSL, Schwingel J, Reichrath J, **Vogt T**, Pföhler C. Report of a case of a familial mediterranean fever with special emphasis on histopathologic characteristics. **Glob Derm** 3(4): 375-378, 2016
4. Krecke N, Zimmer, A, Friesenhahn-Ochs B, Müller CSL, **Vogt T**, Pföhler C. Sneaky side effects and ineffectiveness of an immunotherapy with ipilimumab in a case of metastatic melanoma. Vol 8, e1199307, 2016
5. Burgard B, Vogt T, Müller CSL. Testen Sie Ihr Fachwissen. Ecthyma contagiosum. **Akt Dermatol** 42: 221–223, 2016
6. Pföhler C, Niclou M, Vogt T, Müller CSL. Dermatitis artefacta durch Deospray. **Hautnah Dermatologie** 32:7-8, 2016
7. Pföhler C, Müller CSL, Dorn B, Jakob T, **Vogt T**. Contact anaphylaxis after application of an herbal ointment containing phenonip. **Allergo J Int** 25: 64-65, 2016 **IF 1,31**
8. Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, Sunderkötter C, Kaatz M, Schulte KW, Lehmann P, **Vogt T**, Ulrich J, Herbst R, Gehring W, Simon JC, Keim U, Martus P, Garbe C; German Dermatologic Cooperative Oncology Group (DeCOG). Complete lymph node dissection versus no dissection in patients with sentinel node biopsy positive melanoma (DeCOG-SLT): a multicenter randomized, phase 3 trial. **Lancet Oncol** 2016 May [Epub ahead of print] **IF 24,69**
9. Müller CS, Jungmann J, Pföhler C, Mohammad F, Rübe C, **Vogt T**. Report on immediate irradiation of a rapidly growing sarcoma of the scalp prior to wound closure. **J Dtsch Dermatol Ges** 2016 14:539-542 **IF 2,05**
10. Jungmann J, Heydt C, Bohle R, Pföhler C, **Vogt T**, Müller CS. Genetic basis of a solitary familial plexiform neurofibroma without verified associated neurofibromatosis. **J Dtsch Dermatol Ges** 2016 14(5):525-527 **IF 2,05**

11. Müller CS, Kim YJ, Koch K, Schneider G, Pföhler C, Kohn D, **Vogt T**, Baumhoer D. First report of an aneurysmal bone cyst presenting as subungual mass. *J Cutan Pathol* 2016 Apr (Epub ahead of print) **IF 1,58**
12. Pföhler C, **Vogt T**, Müller CS. Contact allergic gastritis: Rare manifestation of a metal allergy. *Hautarzt* 2016 [Epub ahead of print] **IF 0,56**
13. Mauer S, Pföhler C, Kim YJ, Krenn T, Heine S, **Vogt T**, Müller CS. Multiple granular cell tumors and primitive neuroectodermal tumors (PNETs) - is there a syndromic relationship? *J Dtsch Dermatol Ges* 14(1):59-61, 2016 **IF 2,05**
14. Müller CS, Pföhler C, Cerroni L, Meier CM, **Vogt T**. Fibrous hamartoma of infancy within a congenital nevus. *J Dtsch Dermatol Ges* 13(12):1282-4, 2015 **IF 2,05**
15. Rass K, Frings N, Glowacki P, Gräber S, Tilgen W, **Vogt T**. Same Site Recurrence is More Frequent After Endovenous Laser Ablation Compared with High Ligation and Stripping of the Great Saphenous Vein: 5 year Results of a Randomized Clinical Trial (RELACS Study). *Eur J Vasc Endovasc Surg* 50:648-56, 2015 **IF 2,39**
16. Müller CS, **Vogt T**. Single-stage wound closure of multiple scalp defects using combined advancement flap techniques. *J Dtsch Dermatol Ges* 13(8):829-32, 2015 **IF 2,05**
17. Markeeva E, Hinterberger L, **Vogt T**, Rass K. Combined surgical treatment of a pincer nail with chemical matricectomy, median nail incision, and splinting. *J Dtsch Dermatol Ges* 13(3):256-9, 2015 **IF IF 2,05**
18. Pföhler C, Janssen E, Buecker A, **Vogt T**, Müller CS. Successful treatment of a congenital extra-truncal vascular malformation by orally administered propranolol. *J Dermatolog Treat* 26(1):59-62, 2015 **IF 1,67**
19. Müller CS, Pföhler C, Kohn D, **Vogt T**. Huge undifferentiated fibroblastic sarcoma of the foot and lower leg: impact of diagnostic delay and discussion of an entity. *BMJ Case Rep* 11;2013 **IF**
20. Stanisz H, Pföhler C, **Vogt T**, Müller CS. Disseminated infiltrated pruritic lesions on the body. *Hautarzt* 63:230, 2012 **IF 0,56**
21. Jungmann J, **Vogt T**, Müller CS. Giant verrucous carcinoma of the lower extremity in women with dementia. *BMJ Case Rep* 2012 epub ahead of print **IF -**
22. Schiekofler C, **Vogt T**, Reichrath J. Erythropoietic protoporphyria. A rare differential diagnosis among photosensitive disease. *Hautarzt* 63:961-4, 2012 **IF 0,5**
23. Schiekofler C, Müller CS, Heine S, **Vogt T**, Reichrath J. Monosystemic, oligolesional Langerhans cell histiocytosis. A rare congenital dermatosis. *Hautarzt* 64: 47-51, 2013 **IF 0,5**
24. Müller CS, Tremezaygues L, Pföhler C, **Vogt T**. The spectrum of reticulate pigment disorders of the skin revisited. *Eur J Dermatol* 22:596-604, 2012 **IF 1,76**
25. Zimmer V, Müller CS, Jüngling B, **Vogt T**, Lammert F. Esophageal intramural pseudodiverticulitis in mucous membrane pemphigoid: potential diagnostic utility of Cd4 immunohistochemistry. *Dig Endosc* 24:487, 2012 **IF 1,61**

26. Markeeva E, tremezaygues L, Vogt T, Rass K. Submental transposition flap for a large defect after excision of a recurrent basal cell carcinoma of the chin. **JDDG** 10: 846-8, 2012 **IF 1,4**
27. Hinterberger L, Pfoehler C, **Vogt T**, Müller CS. Diffuse epidermolytic palmoplantar keratoderma (Unna-Thost). **BMJ Case Rep** 2012 epub ahead of print **IF -**
28. Pfoehler C, Körner R, **Vogt T**, Müller CS. Contact allergic gastritis: an underdiagnosed entity? **BMJ Case Rep** 2012 epub ahead of print **IF -**
29. Hinterberger L, Müller CS, **Vogt T**, Pfoehler C. Adalimumab: A treatment option for pyoderma gangraenosum after failure of systemic standard therapies. **Dermatol Ther** (Heidelbg.) 2:6, 2012 **IF -**
30. Müller CS, Schiekofer C, Körner R, Pfoehler C, **Vogt T**. Improved patient centered care with effective use of integra in dermatologic reconstructive surgery. **JDDG** 11:537-48, 2013 **IF 1,4**
31. Tremezaygues L, Borchers JL, Shayesteh-Kheslat R, **Vogt T**, Rass K. Factor XI deficiency: perioperative coagulation management in a patient with an extensive squamous cell carcinoma of the skin. **JDDG** 11:686-8 **IF 1,4**
32. Körner R, Pfoehler C, Vogt T, Müller CS. Histopathology of body art revisited – analysis and discussion of 19 cases. **JDDG** 11:1073-80, 2013 **IF 1,4**
33. Müller CS, Pfoehler C, Kohn D, **Vogt T**. Huge undifferentiated fibroblastic sarcoma of the foot and lower leg: impact of diagnostic delay and discussion of an entity. **BMJ Case Rep** 2013 epub ahead of print **IF -**
34. Pfoehler C, Janssen E, Buecker A, **Vogt T**, Müller CS. Successful treatment of a congenital extra-truncular vascular malformation by orally administered propranolol. **J Dermatol Treat** 2013 epub ahead of print **IF 1,5**
35. Rass K, Frings N, Glowacki P, Hamsch C, Gräber S, **Vogt T**, Tilgen W. Comparable effectiveness of endovenous laser ablation and high ligation with stripping of the saphenous vein. 2-year results of a randomized clinical trial (Relacse study). **Arch Dermatol** 148(1):49-58, 2012 **IF 4,2**
36. Stanisz H, Pfoehler C, Anagnostakos K, Kohn D, **Vogt T**, Müller CS. Metastatic chondrosarcoma - current aspects of a rare event in dermatopathology. **J Cutan Pathol** (epub ahead of print) 2011 **IF 1,7**
37. Pfoehler C, Körner R, Müller CS, **Vogt T**. Occupational allergic contact dermatitis of the ears caused by thiurams in a headset. **Contact Dermatitis**. 65:242-3, 2011 **IF 3,7**
38. Tesmann JP, Thierbach H, Dietrich A, Grimme H, **Vogt T**, Rass K. Radiofrequency induced thermotherapy (RFITT) of varicose veins compared to endovenous laser treatment (EVLT): A non-randomized prospective study concentrating on occlusion rates, side effects and clinical outcome. **Europ J Dermatol** 21:945-51, 2011 **IF 2,4**
39. Trémezaygues L, **Vogt T**, Müller CS. Frontal fibrosing alopecia with androgenetic pattern : A diagnostic challenge - a therapeutic problem. **Hautarzt** (epub ahead of print) 2011 **IF 0,5**
40. Müller CS, Körner R, Takacs FZ, Solomayer EF, **Vogt T**, Pfoehler C. Metastatic breast carcinoma mimicking a sebaceous gland neoplasm: a case report. **J Med Case Reports** (epub ahead of print) 2011 **IF -**

41. Müller CS, Hinterberger LR, **Vogt T**. Successful treatment of Rowell syndrome using oral cyclosporine A. **Int J Dermatol** 50:1020-2, 2011 **IF: 1,3**
42. Körner R, **Vogt T**, Müller CS. Tinea incognita due to Trichophyton mentagrophytes. **JDDG** 9:917-8, 2011 **IF 1,5**
43. Psai S., Pföhler C, **Vogt T**, Müller CSL. Granulomatöse Fremdkörperreaktion nach Augmentation von Aknenarben – eine diagnostische und therapeutische Herkulesaufgabe. **Aktuelle Dermatol** 37:258 - 260, 2011 **IF -**
44. Rass K, Daschzeren M, Gräber S, **Vogt T**, Tilgen W, Frings N. Construction and evaluation of a multidimensional score to assess varicose vein severity – The Homburg Varicose Vein Severity Score (HVSS). **Europ J Dermatol** 21:577-84, 2011 **IF: 2,4**
45. Ziefle S, Egberts F, Heinze S, Volkenandt M, Schmid-Wendtner M, Tilgen W, Linse R, Boettjer J, **Vogt T**, Spith K, Eigentler T, Brockmeyer NH, Heinz A, Hauschild A, Schaefer M. Health related quality of life before and during adjuvant interferon-alpha treatment for patients with melanoma (DeCOG trial). **J Immunother** 34:403-8, 2011 **IF: 3,6**
46. Hinterberger L, Müller CS, **Vogt T**, Pföhler C. Reticulated teleangiectatic erythema after implantation of medical devices: An increasingly occurring phenomenon? **Hautarzt** 62(10):770-3, 2011 **IF: 0,5**
47. Schiekofer C, Müller CSL, Psai S, **Vogt T**, Rass K. Badehauben großes mikrozystisches Adnexkarzinom in Kollision mit einem Bowenkarzinom nach photodynamischer Therapie. **Aktuelle Dermatol** 37:27-30, 2011 **IF: -**
48. Braunert K, Weimann S, Müller CSL, Reichrath J, **Vogt T**. Riesenzellarteriitis der Arteria temporalis links – ausgedehnte Skalpnekrose bei einer 71-jährigen Patientin. **Aktuelle Dermatol** 37:24-26, 2011 **IF: -**
49. Markeeva E, Müller CSL, **Vogt T**, Rösch A. Lymphomatoide Papulose Typ A: Ist weniger (Therapie) mehr? **Aktuelle Dermatol** 37:19-21, 2011 **IF: -**
50. Weimann S, **Vogt T**, Pföhler C. Biss einer Ammendornfingerspinne – eine zukünftig häufiger zu stellende Diagnose? **Aktuelle Dermatol** 37:22-23, 2011 **IF: -**
51. Klein A, **Vogt T** (equal contr.), Wenzel S, Fleck M, Landthaler M. Cyclosporine combined with MTX in two patients with recalcitrant subacute cutaneous lupus erythematosus. **Australas J Dermatol** 52: 43-47, 2011 **IF 1,0**
52. Müller C, Janssen E, Schmaltz R, Körner H, **Vogt T**, Pföhler C. Multisystemic Langerhans cell histiocytosis presenting as chronic scalp eczema – clinical management and current concepts. **J Clin Oncol** 29:539-42, 2011 **IF 19,0**
53. Müller CS, Schmaltz R, **Vogt T**, Pföhler C. Lichen striatus and Blaschkitis: reappraisal of the concept of Blaschkoliner dermatoses. **Br J Dermatol** 164:257-62, 2011 **IF 4,4**
54. Müller CS, Schmaltz R, **Vogt T**, Pföhler C. Expression of CD30 antigen in superficial mycotic infections of the skin: a possible non-specific finding without clinical relevance. **Mycoses** 54:360-3, 2010 **IF 1,7**
55. Schmaltz R, Müller CS, **Vogt T**. [Sudden growth of previously indolent scalp nodule]. **Hautarzt** 61:518-21, 2010 **IF: 0,5**

56. Müller CS, Schmaltz R, **Vogt T**. Secondary cutaneous cryptococcosis mimicking a malignant ulcerated tumor of the facial skin in an immunosuppressed patient. **Eur J Dermatol** 20:657-8, 2010 **IF 2,4**
57. Schmaltz R, **Vogt T**, Müller CSL. Plaque-Like Sclerodermiform localized mucinosis rapidly responsive to topical tacrolimus. **Case Rep Dermatol** 2:165-168, 2010 **IF --**
58. Härle P, Hartung W, Lehmann P, Ehrenstein B, Schneider N, Müller H, Müller-Ladner U, Tarner I, **Vogt T**, Fleck M, Bongartz T. Detection of psoriasis arthritis with the GEPARD patient questionnaire in a dermatologic outpatient setting. **Z Rheumatol** 69:157-60, 162-3, 2010 **IF 0,5**
59. Hauschild A, Weichenthal M, Rass K, Linse R, Berking C, Boettjer J, **Vogt T**, Spieth K, Eigentler T, Brockmeyer NH, Stein A, Näher H, Schadendorf D, Mohr P, Kaatz M, Tronnier M, Hein R, Schuler G, Egberts F, Garbe C. Efficacy of Low-dose Interferon alpha 2a 18 versus 60 Months of Treatment in Patients with Primary Melanoma of ≥ 1.5 mm Tumor Thickness: Results of a Randomized Phase III DeCOG Trial. **J Clin Oncol** 10:841-6, 2010 **IF 19,0**
60. Klein A, Wenzel SM, Messmer EM, Landthaler M, **Vogt T**. Linear IgA disease with ocular involvement associated with ulcerative colitis. **Hautarzt** 61:55-7, 2010 **IF: 0,5**
61. Heinze S, Egberts F, Rötzer S, Volkenandt M, Tilgen W, Linse R, Boettjer J, **Vogt T**, Spieth K, Eigentler T, Brockmeyer NH, Hinzpeter A, Hauschild A, Schaefer M. Depressive Mood Changes and Psychiatric Symptoms During 12-month Low-dose Interferon-alpha Treatment in Patients With Malignant Melanoma: Results From the Multicenter DeCOG Trial. **J Immunother** 33:106-14, 2009 **IF 3,2**
62. Babilas P, Schreml S, Landthaler M, **Vogt T**. A 12-month-old boy with impaired pigmentation. Diagnosis: nevus depigmentosus. **Ped Annals** 38:617-21, 2009 **IF 2,1**
63. Hauschild A, Weichenthal M, Rass K, Linse R, Ulrich J, Volkenandt M, Grabbe S, Proske U, Schadendorf D, Brockmeyer N, **Vogt T**, Rompel R, Kaufmann R, Kaatz M, Näher H, Mohr P, Eigentler T, Livingston E, Garbe C. Prospective-randomized multicenter adjuvant DeCOG trial on low-dose IFN alpha2b with or without a modified high-dose IFN alpha2b induction phase in lymph node negative melanoma patients. **J Clin Oncol** 27:3496-502, 2009 **IF 17,8**
64. Ebert AK, Rösch WH, Vogt T. Safety and tolerability of adjuvant topical tacrolimus treatment in boys with lichen sclerosus: a prospective phase II study. **Europ Urol** 54(4):932-7, 2008 **IF: 4,9**
65. Schroeder JA, Weingart C, Coras B, Hausser I, Reinhold S, Mack M, Seybold V, Vogt T, Banas B, Hofstaedter F, Krämer BK. Ultrastructural evidence of dermal Gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. **Clin J Am Soc Nephrol** 3(4):968-75, 2008 **IF: 4,4**
66. Ebert AK, Vogt T, Rösch WH. Topical therapy of balanitis xerotica obliterans in childhood : Long-term clinical results and an overview. **Urologe A** 46:1682-1686, 2007 **IF: 0,8**
67. Reichle A, **Vogt T**, Coras B, Terheyden P, Neuber K, Trefzer U, Schultz E, Berand A, Bröcker EB, Landthaler M, Andreesen R.. Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: A randomized phase II trial. **Melanoma Res** 17:360-364, 2007 **IF: 2,2**

68. Ulrich H, Landthaler M, **Vogt T**. Granulomatous jellyfish dermatitis. **JDDG** 5:493-5, 2007. IF: -
69. Meyer S, **Vogt T**, Landthaler M, Karrer S. Cutaneous pseudolymphoma induced by cimicifuga racemosa. **Dermatology** 214:94-6, 2007 IF: 1,2
70. Coras B, **Vogt T (equal contr.)**, Roesch A, Landthaler M, Hohenleutner U. Bowen`s disease on porokeratotic eccrine ostial and dermal duct nevus (PEODDN). **Dermatol Surg**, 33:496-9, 2007 IF: 1,8
71. Schadendorf D, Hauschild A, Ugurel S, Thoelke A, Egberts F, Kreissig M, Linse R, Trefzer U, Vogt T, Tilgen W, Mohr P, Garbe C. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. **Ann Oncol** 17:1592-7, 2006 IF: 3,6
72. **Vogt T**, Coras B, Hafner C, Landthaler M, Reichle A. Antiangiogenic and antiinflammatory palliative therapy in a case of metastatic prostate carcinoma complicated by paraneoplastic subacute cutaneous lupus erythematoses. **Lancet Oncol** 7: 695 -697, 2006 IF: 6,8
73. Coras B, Roesch A, Koschorreck L, Landthaler M, **Vogt T**. Post-traumatic iatrogenic aggravation of eruptive collagenomas in a child. **Eur J Dermatol** 16: 196-197, 2006 IF 1,0
74. Meyer S, Landthaler M, **Vogt T**. Thymoma, myasthenia gravis, eruptions of pemphigus vulgaris and a favourable course of relapsing melanoma: an immunologic puzzle. **Br J Dermatol** 155:638-40, 2006 IF 2,7
75. Hafner C, Landthaler M, **Vogt T**. Targeting T-cells to hit B-cells: successful treatment of cutaneous plasmocytosis with topical pimecrolimus. **Dermatology** 213:163-5, 2006 IF 1,2
76. Hafner C, Landthaler M, **Vogt T**: Lichen striatus (blaschkitis) following varicella infection. **JEADV**, 20: 1328-1399, 2006 (letter) IF 1,4
77. Hafner C, Koellner K, **Vogt T**, Landthaler M, Szeimies M: Ein Fall von hämorrhagischem Denguefieber nach Malaysiaaufenthalt. **Hautarzt** 57:705-7, 2006 IF 0,52
78. Kaufmann R, Spieth K, Leiter U, Mauch C, von den Driesch P, **Vogt T**, Linse R, Tilgen W, Schadendorf D, Becker JC, Sebastian G, Krengel K, Kretschmer L, Garbe C, Dummer R. Temozolomide in combination with interferon alfa versus temozolomide alone in patients with advanced metastatic melanoma: A randomized phase III multicenter study of the Dermatologic Cooperative Oncology Group (DeCOG). **J Clin Oncol**, 23(35):9001-7, 2005 IF 10,9
79. Coras B, **Vogt T**, Ulrich H, Landthaler M, Hohenleutner U. Fumaric acid esters therapy: a new treatment modality in pityriasis rubra pilaris (letter). **Br J Dermatol** 152:368-403, 2005 IF 2,7
80. Roesch A, Haegele T, **Vogt T**, Babilas P, Landthaler M, Szeimies RM. Severe contact urticaria to guar gum included as gelling agent in a local anesthetic. **Contact Derm**, 52:307-8, 2005 IF 1,10
81. Meyer S, Zanardo Z, Kaminski WE, Horn P, Schmitz G, Hohenleutner U, Herrmann WA, Landthaler M, **Vogt T**. Elastosis perforans serpiginosa-like pseudoxanthoma elasticum in a child with severe Moya Moya disease. **Br J Dermatol**, 153:431-434, 2005 IF 2,7

82. Bongartz T, Härle P, Karrer S, **Vogt T**, Seitz A, Müller-Ladner U: Successful Treatment of Psoriatic Onycho-Pachydermo Periostitis (POPP) with Adalimumab **Arthritis Rheum**, 52:280-282, 2005 **IF 7,4**
83. Bongartz T, Coras B, **Vogt T**, Schölmerich J, Müller-Ladner U. Treatment of Active Psoriatic Arthritis with the PPAR γ -Ligand Pioglitazone: an Open Label Pilot Study. **Rheumatology**, 44: 126-129, 2005 **IF 3,8**
84. Coras B, Eßbauer S, Pfeffer M, Meyer H, Schröder J, Stolz W, Landthaler M, **Vogt T**. Cowpox and a cat. **THE LANCET**, 365:446, 2005 **IF 21,7**
85. Reichle A, **Vogt T**, Kunz-Schunghart L, Bachthaler M, Bretschneider T, Bross K, Freund S, Napiralski S, Berand A, Andreesen R. Anti-inflammatory and angiostatic therapy in chemorefractory multisystem Langerhans cell histiocytosis of adults. **Br J Hematol**, 128,730-736, 2005 **IF 3,3**
86. Meyer S, Naumann L, Landthaler M, **Vogt T**. Mycobakterium bovis caprae an unusual cause of lupus vulgaris. **Br J Dermatol** 153:220-2, 2005 **IF 2,7**
87. Hafner C, Wimmershoff M, Landthaler M, **Vogt T**. Lipodermatosclerosis: successful treatment with danazol. (letter) **Acta Derm Venereol** 85:365-6, 2005 **IF 1,6**
88. Hafner C, Linde H-J, **Vogt T**, Breindl G, Koellner K, Tintelnot K, Landthaler M, Szeimies M. Primary cutaneous cryptococcosis and secondary antigenemia in a patient with long term corticosteroid therapy. **Infection**, 33: 86-89, 2005 **IF 1,0**
89. Meyer S, Burgdorff T, Szeimies M, **Vogt T**, Landthaler M, Karrer S. Management of erosive lichen planus with topical tacrolimus and recurrence secondary to metoprolol. **JEADV** 19:236-9, 2005 **IF 1,4**
90. Babilas P, Szeimies RM, Landthaler M, **Vogt T**. Zosteriforme Pigmentpurpura Schamberg: Ein Fallbericht und die Differentialdiagnose zosteriformer Hautveränderungen. **JDDG**, in press **IF –**
91. Roesch A, Linde J, Landthaler M, **Vogt T**. cMRSA eradication in a nurse with atopic dermatitis. **Arch Dermatol**, 141:1520-2, 2005 **IF 3,5**
92. Coras B, Hafner C, Roesch A, **Vogt T**, Landthaler M, Hohenleutner U. Congenital cartilaginous rests of the neck (wattles). **J Derm Surg** 31:1349-50, 2005 **IF 1,8**
93. Reichle A, Bross K, **Vogt T**, Bataille F, Wild J, Berand A, Krause S, Andreesen R. Pioglitazone and rofecoxib combined with angiostatic scheduling of trofosfamide in far advanced malignant melanomas and soft tissue sarcomas. **Cancer** 101:2247-56, 2004 **IF 4,0**
94. Coras B, Hafner C, Reichle A, Hohenleutner U, Szeimies RM, Landthaler M, **Vogt T**. Antiangiogenic therapy with pioglitazone, rofecoxib and trofosfamide in a patient with endemic Kaposi's sarcoma. **Arch Dermatol** 140:1504-1507, 2004 **IF 3,5**
95. Roesch A, Schleyer V, Landthaler M, **Vogt T**. Follicular mycosis fungoides (FMF): Variability of a rare entity. **Skinmed** 4:12-17, 2005 **IF --**
96. Meurer M, Fartasch M, Albrecht G, **Vogt T**, Worm M, Ruzicka T, Altmeyer PJ, Schneider D, Weidinger G, Braeutigam M, For The CASM-DE-01 Study Group F. Long-Term Efficacy and Safety of Pimecrolimus Cream 1% in Adults with Moderate Atopic Dermatitis. **Dermatology** 208(4):365-372, 2004 **IF 1,2**

97. **Vogt T**, Durnick A, Stolz W, Landthaler M. Lentigo maligna and lentigo maligna melanoma in young adults. **Dermatol Surg**, 30:813-6, 2004 **IF 1,8**
98. Zanardo L, Stolz W, Schmitz G, Kaminski W, Vikkula M, Landthaler M, **Vogt T**. Progressive hyperpigmentation and generalized lentiginosis without associated systemic symptoms: a rare hereditary pigmentation disorder in south-east Germany. **Acta Derm Venereol** 84:57-60, 2004 **IF 1,6**
99. **Vogt T**, Hafner C, Bross K, Bataille F, Jauch KW, Berand A, Landthaler M, Andreesen R, Reichle A. Antiangiogenic therapy with pioglitazone, rofecoxib, and metronomic trifluoromethylthymine in patients with advanced malignant vascular tumors. **Cancer** 98:2251-6, 2003 **IF 4,0**
100. Coras B, **Vogt T** (equal contribution), Hohenleutner U, Landthaler M, Karrer S. Porokeratotic eccrine ostial and dermal duct nevus (PEODDN). **JDDG**, 1:797-800, 2003 **IF --**
101. **Vogt T**, Brunnberg S, Hohenleutner U, Landthaler M. Bullous malignant melanoma: an unusual differential diagnosis of a hemorrhagic friction blister. **J Dermatol Surg** 29:102-4, 2003 **IF 1,8**
102. Bogenrieder T, Rogler G, **Vogt T**, Landthaler M, Stolz W. Orofacial granulomatosis as the initial presentation of Crohn's disease in an adolescent. **Dermatology** 206:273-8, 2003 **IF 1,2**
103. Douwes KE, Schmalzbauer E, Linde HJ, Reisberger EM, Fleischer K, Lehn N, Landthaler M, **Vogt T**. Branched filaments no fungus, ovoid bodies no bacteria – two unusual cases of mycetoma. **J Am Acad Dermatol**, 49:170-173, 2003 **IF 3,0**
104. Burgdorff T, Venemalm L, **Vogt T**, Landthaler M, Stolz W. IgE-mediated anaphylactic reaction induced by succinate ester of methylprednisolone. **Ann Allergy Asthma Immunol** 89:425-428, 2002 **IF 2,2**
105. Zanardo L, Stolz W, Landthaler M, **Vogt T**. Reactive perforating collagenosis after disseminated zoster. **Dermatology**, 203:273-5, 2001 **IF 1,2**
106. Kroiss M, **Vogt T (Corresponding author)**, Finkenzeller X, Landthaler M, Stolz W. Psoriatische Onycho-Pachydermoperiostitis. **Z Rheumatol**, 60:1-3, 2001 **IF 0,5**
107. Douwes KE, Burgdorff T, Szeimies RM, Messmann H, **Vogt T**, Landthaler M. Paraneoplastische Akrokeratose Bazex bei Adenokarzinom des Magens. **D Med Wschr**, 126:203-206, 2001 **IF 0,7**
108. Reisberger E, Douwes K, Landthaler M, **Vogt T**. Anstrengungsinduzierte leukozytoklastische Vaskulitis. **Z Haut&G**, 76: 96-100, 2001 **IF --**
109. Mehringer S, **Vogt T**, Jabusch HC, Kroiss M, Fürst A, Schölmerich J, Messmann H. Treatment of panniculitis in chronic pancreatitis by interventional endoscopy following extracorporeal lithotripsy. **Gastrointest Endoscopy**, 53:104-107, 2001 **IF 3,3**
110. Gruss C, Zillikens D, Hashimoto T, Amagai M, Kroiß M, **Vogt T**, Landthaler M, Stolz W. Rapid response of IgA pemphigus of subcorneal pustular dermatosis type to treatment with isotretinoin. **J Am Acad Dermatol**, 43:923-926, 2000 **IF 3,0**

111. Kroiss M, **Vogt T**, Landthaler L, Stolz W. Low-dose intravenous immune globulin (IVIG) is effective in chronic urticaria. (letter) **Acta Dermatol Venereol** 80:225, 2000 **IF 1,6**
112. Gläßl A, Hohenleutner U, Landthaler M, **Vogt T**. Bazex-Dupre-Christol-like-syndrome. **Dermatol Surg** 26:152-154, 2000 **IF 1,8**
113. Kroiss M, **Vogt T**, Landthaler L, Stolz W. High-dose intravenous immune globulin (IVIG) is also effective in linear IgA bullous dermatosis. (letter) **Br J Dermatol** 142: 582, 2000 **IF 2,7**
114. **Vogt T**, Landthaler M, Stolz W. Sodium-benzoate induced leucocytoclastic vasculitis with unusual clinical appearance. **Arch Dermatol** 135: 726-7, 1999 **IF 3,5**
115. **Vogt T**, Landthaler M, Stolz W: Generalized eczema in a 1 ½ year old boy due to phenoxyethanol in DTP vaccine. **Contact Dermatitis** 38:50-51, 1998 **IF 1,1**
116. **Vogt T**, Stolz W, Landthaler M: Aplasia cutis congenita after exposure to methimazole. A causal relationship? **Br J Dermatol** 133:994-996, 1995 **IF 2,7**
117. Dummer R, Röger J, **Vogt T**, Becker J, Hefner H, Sindermann H, Burg G: Topical application of hexadecylphosphocholine in patients with cutaneous lymphomas. **Prog Exp Tumor Res** 34:160-169, 1992 **IF -**

D Übersichten/Buchbeiträge – chronologisch (48/22)

1. Ü Müller CSL, Kim YJ, **Vogt T**, Pföhler C. Systemvaskulitides II: Diagnostik und histologische Besonderheiten. **Akt Dermatol** 42: 360-373, 2016
2. Ü Müller CSL, **Vogt T**, Pföhler C. Systemvaskulitides I: Diagnostik und histologische Besonderheiten der kutanen Vaskulitiden/Vaskulopathien. **Akt Dermatol** 42: 360-373, 2016
3. Ü Reichrath J, Holick M, Zouboulis C, **Vogt T**. Targeting the Vitamin D Endocrine System (VDES) for the management of inflammatory and malignant skin diseases: an historical view and outlook. **Rev Endocrine Metabolic Disorders** 2016 accepted, **IF 4,89**
4. Ü Reichrath J, Berg K, Emmert S, Lademann J, Seckmeyer G, Zastrow L, **Vogt T**, Holick MF. Biologic Effects of Light: An Enlightening Prospective. **Anticancer Res** 36(3):1339-43, 2016 **IF 1,83**
5. Ü Pföhler C, **Vogt T**, Müller CS. Malignant head and neck melanoma Part 1: Diagnosis and histological particularities. **HNO** 63(7):523-34, 2015 **IF 0,58**
6. Ü Pföhler C, **Vogt T**, Müller CS. Malignant head and neck melanoma Part 2: Therapy. **HNO** 63(8):593-602, 2015 **IF 0,58**
7. Ü South Sea Atolls. Kerber AU, **Vogt T**, Müller CS. **Am J Dermatopathol** 37(11):850-1, 2015 **IF 1,39**
8. Ü Meyer V, **Vogt T**, Rass K. Vergleich der endovenösen Laserablation mit Crossektomie und Stripping. **Aktuelle Dermatologie** 40: 499-503, 2014 **IF -**

9. Ü Vogt T. Therapy of metastatic malignant melanoma: on the way to individualized disease control. **Adv Exp Med Biol** 810:272-81, 2014 **IF 1,96**
10. Ü Reichrath J, Reichrath S, Heyne K, **Vogt T**, Roemer K. Tumor suppression in skin and other tissues via cross-talk between vitamin D- and p53-signaling. **Frontiers in Physiol** (article 166) 5: 1-10 2014 **IF -**
11. **B Vogt T**. Therapy of metastatic malignant melanoma: On the way to individualized disease control. In: Reichrath R (ed.) Sunlight, Vitamin D and skin cancer, 2nd ed. (in press 2013).
12. Ü **Vogt T**, Brockmeyer N, Kutzner H, Schöfer H. Brief S1 guidelines – Cutaneous angiosarcoma and Kaposi sarcoma. **JDDG** 11 Suppl 3: 2-9, 2013 **IF 1,81**
13. Ü Reich-Schupke S, Alm J, Altmeyer P,**Vogt T**, et.al. Phlebology in German departments of dermatology. An analysis on behalf of the German Society of Phlebology. **Hautarzt** 64: 685-94, 2013 **IF 0,56**
14. Ü Reichrath J, Friedrich M, **Vogt T**. Vitamin D and ist analogs in cancer prevention and therapy. **Anticancer Res** 32:209-10, 2012 **IF 1,83**
15. Ü **Müller CS**, Niclou M, **Vogt T**, Pföhler C. Lipedematous diseases of the scalp are not separate entities but part of a spectrum of lipomatous lesions. **J Dtsch Dermatol Ges** 10:501-7, 2012 **IF 1,4**
16. Ü Beek NV, Knuth-Rehr D, Altmeyer P, Assaf C, Babilas P, Bayerl C, Benoit S, Dippel E, Effendy I, Eming R, Fischer M, Glaenz T, Gläser R, Goebeler M, Gollnick H, Götze S, Gross G, Hadaschik E, Herbst R, Hermes B, Homey B, Hunzelmann N, Jünger M, Kapp A, Kern JS, Körber A, Luger T, Mechtel D, Megahed M, Moll I, Peters KP, Pfeiffer C, Ring J, Röcken M, Sárdy M, Seitz C, Stadler R, Steinbrink K, Sticherling M, Szeimies RM, Tronnier M, Ulrich J, **Vogt T**, Wagner N, Welzel J, Wenzel J, Wozel G, Zouboulis CC, Zillikens D, Schmidt E. Diagnostics of autoimmune bullous diseases in German dermatology departments. **J Dtsch Dermatol Ges** 10:492-9, 2012 **IF 1,4**
17. Ü Denzer N, **Vogt T**, Reichrath J. Vitamin D receptor (VDR) polymorphisms and skin cancer: A systematic review. **Dermatoendocrinol** 3(3):205-10, 2011 **IF -**
18. Ü Tremezaygues LL, **Vogt T**, Reichrath J. Vitamin D und seine Wirkung in der Haut. **Der Deutsche Dermatologe** 59: 1-5, 2011 **IF -**
19. Ü **Vogt T**. Arzneimittelnebenwirkungen. Medikamente als Auslöser von Mundschleimhaut-Beschwerden. **Der Deutsche Dermatologe** 59: 488-96, 2011 **IF -**
20. Ü **Vogt T**. Hauttumoren. Schlüssel-moleküle für zielgerichtete Therapien. **MedReport** 7/35: 15, 2011 **IF -**
21. Ü Schmaltz R, **Vogt T**, Reichrath J. Skin manifestations in Tumor necrosis factor receptor-associated periodic syndrome (TRAPS). **Dermatoendocrinology** 2:26-29, 2010 **IF -**
22. Ü Roesch A, **Vogt T**. Melanomstammzellen – ein neuer Forschungsschwerpunkt der Universitätshautklinik des Saarlandes. **Aktuelle Dermatol** 37:9-11, 2011 **IF: -**
23. Ü Trémezaygues L, **Vogt T**, Reichrath J. Endokrines Vitamin D System in der humanen Haut. **Aktuelle Dermatol** 37:12-18, 2011 **IF: -**

24. Ü **Vogt T.** (Editorial) Klinik für Dermatologie, Venerologie und Allergologie des Saarlandes: Fortsetzung der tradierten Linie mit neuen wissenschaftlichen und klinischen Akzenten. **Aktuelle Dermatol** 37:1-2, 2011 **IF: -**
25. Ü Trémezaygues L, Schmaltz R, **Vogt T**, Reichrath J. Management of pyoderma gangrenosum. An update on clinical features, diagnosis and therapy] **Hautarzt**. 61:345-53, 2010 **IF 0,45**
26. **B** **Vogt T.** Unerwünschte Arzneimittelnebenwirkungen im Orofazialbereich. In: Balogh A, Haen E. (eds.), *Klinische Pharmakologie in der zahnärztlichen Praxis*, Wiss. Verlagsgesellschaft Stuttgart, 2010 pp. 191 – 203
27. **B** Reichle A, **Vogt T.** Systems biology: A therapeutic target for tumor therapy. In: Reichle A. (ed.) *From molecular to modular tumor therapy*. Springer, London, New York, 2010, 265-286
28. **B** Reichle A, **Vogt T**, Hildebrandt GC. A methodological approach to personalized therapies in metastatic cancer. In: Reichle A. (ed.) *From molecular to modular tumor therapy*. Springer, London, New York, 2010, 507 - 536
29. **B** **Vogt T.** Angiosarkom. In: Szeimies RM, Hauschild A, Garbe C, Kaufmann R, Landthaler M. (eds.), 1. Auflage Thieme, Stuttgart , 2010 pp. 638-642
30. **B** Hafner C, **Vogt T.** Antiangiogenese. In: Szeimies RM, Hauschild A, Garbe C, Kaufmann R, Landthaler M. (eds.), 1. Auflage Thieme, Stuttgart , 2010 pp. 270-277
31. Ü Schreml S, Szeimies RM. **Vogt T**, Landthaler M, Schröder J, Babilas P. Cutaneous amyloidoses and systemic amyloidoses with cutaneous involvement. **Eur J Dermatol** 20(2):152-60, 2009 **IF -**
32. Ü Bundscherer A, Reichle A, Hafner C, Meyer S, **Vogt T.** Targeting the Tumor Stroma with Peroxisome Proliferator Activated Receptor (PPAR) agonists. **Anti-Cancer Agents in Medicinal Chemistry** 9:816-21, 2009 **IF -**
33. **B** **Vogt T.** Papular and lichenoid diseases. In: **Braun Falco's Dermatology**. Braun-Falco O, Plewig G, Wolff HH, Landthaler M. (eds.), 3. edition ff, Springer, Heidelberg, 2009 pp. 527-539
34. Ü Vogt T, Brockmeyer N, Kutzner H, Schöfer H. Short German guidelines: angiosarcoma and Kaposi sarcoma. **JDDG** 6 Suppl 1:S19-24, 2008.
35. Ü Reichle A, **Vogt T.** Systems biology: A therapeutic target for tumor therapy. **Cancer Microenviron** 1(1):159-70, 2008
36. Ü **Vogt T**, Landthaler M. Reichle A, Rösch A. Die Melanomstammzelle – Würdigung eines radikal neuen Konzepts. **Journal Onkologie** 4: 203-207, 2008
37. Ü **Hafner C, Vogt T.** Die seborrhoische Keratose. **JDDG** 6(8):664-77, 2008 **IF -**
38. Ü **Vogt T.** Angiosarkome. **Hautarzt** 59:237-51, 2008 **IF 0,36**
39. Ü Ulrich H, Landthaler M, **Vogt T.** Aquatic dermatoses. **JDDG** 6:133-46, 2008 **IF -**

40. **B Vogt T**, Brockmeyer N, Kutzner H, Schöfer H. G6 Angiosarkom und Kaposi Sarkom. In: **Deutsche Krebsgesellschaft (Hrg.), Kurzgefasste interdisziplinäre Leitlinien 2008**. pp 159-169 W. Zuckschwerdt, München Wien, New York
41. **Ü** (Comment) Hafner C, Hartmann A, **Vogt T**. *FGFR3* Mutations in Epidermal Nevi and Seborrheic Keratoses: Lessons from Urothelium and Skin. **J Invest Dermatol** 127, 1572–1573, 2007
42. **Ü** Roesch A., **Vogt T**. New molecular biomarkers for malignant melanoma. **G Ital Dermatol Venereol** 142:109-21, 2007
43. **B** Hafner C, **Vogt T**, Reichle A. Conventional therapeutics with antiangiogenic activity. In: Davis (Ed.) **Antiangiogenic cancer therapy**. CRC press, Boca Raton, London, New York 2007 pp 301-327
44. **Ü** Bundscherer A, Hafner C, **Vogt T**. Stroma targeted therapy: an emerging new concept in tumor palliation. Epub. www.siicsalud.com in the Section **Invited Experts**. IF: -
45. **B Vogt T**. Tumorerkrankungen der Haut. In: J. Schölmerich (Hrg.) III. überarbeitete Auflage. **Medizinische Therapie in Klinik und Praxis**. Springer, Heidelberg, 2007 pp.1621-1631
46. **Ü** Hafner C, Hartmann A, Landthaler M, **Vogt T**. *FGFR3* mutations in benign skin tumors. **Cell Cycle**, 5:23 2723-2728, 2006 IF: -
47. **Ü** Bundscherer A, Hafner C, **Vogt T**. Neue stromaorientierte Therapieoptionen in der palliativen Tumorthherapie. **J Onkologie** 05: 26-32, 2006 IF: -
48. **Ü** Hafner C, Landthaler M, **Vogt T**. Multimodale Stroma-orientierte Tumorthherapie. **JDDG** 4:242-53, 2006
49. **Ü** Rösch A, Burgdorf W, Stolz W, Landthaler M, **Vogt T**. Dermatoscopy of “dysplastic nevi”: A beacon in diagnostic darkness. **Eur J Dermatol** 16:479-93 2006
50. **B Vogt T**. Bösartige Neubildungen der Haut. In: Reuter (Hrg.) **Springer Lexikon Diagnose Therapie**. Springer, Heidelberg, 2006 pp 993 - 1003
51. **Ü** Vogl A, Landthaler M, **Vogt T**. Haut und Alkohol. **JDDG** 3:788-809, 2005
52. **Ü** Hafner C, Reichle A, **Vogt T**. New indications for established drugs: Combined tumor-stroma-targeted cancer therapy with PPAR γ -agonists, Cox-2 inhibitors, mTOR Antagonists and metronomic chemotherapy. **Current Cancer Drug Targets** 5: 393-419, 2005
53. **Ü** Becker B, Landthaler M, **Vogt T**. Molekularbiologische Profiling-Methoden in der Dermatologie. **JDDG** 3:448-464, 2005
54. **B Vogt T**. Lichen ruber und lichenoide Exantheme. In: **Dermatologie und Venerologie**. Braun-Falco O, Plewig G, Wolff HH, Burgdorf W, Landthaler M. (Hrg.), 5. Auflage und ff., Springer, Heidelberg, 2005 pp. 498-513
55. **B Vogt T**. Tumorerkrankungen der Haut. In: J. Schölmerich (Hrg.) II. überarbeitete Auflage. **Medizinische Therapie in Klinik und Praxis**. Springer, Heidelberg, 2005 pp.1405-13

56. Ü Meyer S, **Vogt T**, Landthaler M, Karrer S. Einsatz von Phytopharmaka in der Dermatologie. Indikationen, Therapiehinweise und Nebenwirkungen. **Hautarzt** 56:483-502, 2005
57. B Hafner C, **Vogt T**, A Hartmann. Clonality analysis of tumors using DNA related techniques. In: Woods R.C. (ed.): **Focus in DNA Research**, Nova Science Publ., 2005 und pp 79-98.
58. B (Hrg.) Landthaler M, **Vogt T**, Hohenleutner U. Klinische und histologische Klassifikation benigner vaskulärer Fehl- und Neubildungen der Haut. In: Landthaler M, Hohenleutner U, **Vogt T** (Hrg.). 2. Auflage. **Benigne Gefäßfehl- und Neubildungen der Haut. Interdisziplinäre Diagnostik und Therapie**. Thieme, Stuttgart, 2004 pp. 31-44
59. B **Vogt T**, Stolz W. Tumorerkrankungen der Haut. In: J. Schölmerich (Hrg.) **Medizinische Therapie in Klinik und Praxis**. Springer, Heidelberg, 2003 pp. 1437-45
60. B Stolz W, **Vogt T**, Landthaler M. Störungen der Melaninpigmentierung. In: Kerl H, Garbe C, Cerroni L, Wolf HH (hrg.) Springer, Berlin, Heidelberg, New York 2003 pp. 531 – 541
61. B Landthaler M, **Vogt T**, Hohenleutner U. Klinische und histologische Klassifikation benigner vaskulärer Fehl- und Neubildungen der Haut. In: Landthaler M, Hohenleutner U, **Vogt T** (Hrg.). **Benigne Gefäßfehl- und Neubildungen der Haut. Interdisziplinäre Diagnostik und Therapie**. Blackwell, Berlin, 2002 pp. 31-44
62. Ü Roesch A, Landthaler M, **Vogt T**. [The dysplastic nevus. Separate entity, melanoma precursor or diagnostic dilemma?]. **Hautarzt** 54:871-83, 2003
63. Ü Hafner C, Meyer S, **Vogt T**. [Mechanisms of epithelial regeneration]. **Hautarzt** 53:561-74, 2002
64. Ü Meyer S, Hafner C, **Vogt T**. [Role of receptor tyrosine kinases in the angiogenesis]. **Hautarzt** 53:629-42, 2002
65. B **Vogt T**, Kroiss M, Guba M[#], Becker B, Landthaler M, Stolz W: Quantum leaps in expression genetics: From RNA fingerprinting to cDNA array technology. **Proceedings of the 10th European Academy of Dermatology and Venerology**, Monduzzi, Bologna, 2002, pp 123-125
66. B **Vogt T**. Kutane Lymphome. In: **1. SymPro: Leitlinien des Tumorzentrums Regensburg**, Tumorzentrum Regensburg e.V. (Hrg.). Regensburg, 1999 und 2000, pp30-42
67. B **Vogt T**, Mathieu-Daude F, Kullmann F, Welsh J, McClelland M. Arbitrarily primed PCR of DNA and RNA. In: **DNA Markers: Protocols, Applications and Overviews**, Caetano-Anolles G and Gresshoff PM (eds.), J. Wiley & Sons, New York, NY, 1997, pp 55-74
68. B Mathieu-Daude F, Evans K, Kullmann F, Honeycutt R, **Vogt T**, Welsh J, McClelland M. DNA and RNA fingerprinting by the arbitrarily primed polymerase chain reaction. In: **Bacterial Genomes, Physikal Structure and Analysis**, de Bruijn FJ, Lupski JR, Weinstock GM (eds.), Chapman & Hall, New York, NY, 1997, pp 414-436
69. B Stolz W, **Vogt T**, Landthaler M, Abmayr W: Computerized quantitative dermatopathology. In: **Computer Applications in Dermatology**, Stoecker W (ed.). Igaku-Shoin, New-York, Tokyo, 1993, pp 117-147

